What happens when breakthrough drugs collide with outdated systems of access?

In this episode, Ipsos' Kiran Khepar and Neil Grubert, Global Market Access Consultant, explore the friction between innovation and access, and what it means for the future of healthcare systems.

GLP-1 therapies are redefining what’s possible in obesity treatment, but reimbursement pathways haven’t caught up. From out-of-pocket models to public payer resistance, we’re unpacking how market dynamics are shaping who really gets treated and who’s left behind.